Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candiRead More
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
